Background: Proper functioning of the meniscus depends on the composition and organization of its fibrocartilaginous extracellular matrix. We previously demonstrated that the avascular inner meniscus has a more chondrocytic phenotype compared with the outer meniscus. Inhibition of the Rho family GTPase ROCK, the major regulator of the actin cytoskeleton, stimulates the chondrogenic transcription factor Sry-type HMG box (SOX) 9-dependent α1(II) collagen (COL2A1) Conclusions: This study demonstrated that ROCK inhibition stimulated SOX9/Smad3-dependent COL2A1 expression through the immediate nuclear translocation of Smad3 in inner meniscus cells.
Introduction
The meniscus is a fibrocartilaginous tissue that plays an important role in controlling complex biomechanics of the knee [1] . Proper functioning of the meniscus depends on the composition and organization of its extracellular matrix (ECM) [2] . Type I collagen accounts for more than 90% of the total meniscal collagen and is present throughout the entire meniscus. On the other hand, type II collagen is restricted to the inner avascular region of the meniscus [2] [3] [4] . However, the distributions of types I and II collagen in human menisci are different from those in rabbit and sheep menisci [5] . We previously demonstrated that the avascular inner meniscus has a more chondrocytic phenotype compared with the outer meniscus [6, 7] . In addition, human inner meniscus cells have chondrocytic morphology and an ability to produce type II collagen, a cartilage-specific ECM component [6] [7] [8] [9] . Physiological biomechanical stress induces α1(II) collagen (COL2A1) expression through the activation of the chondrogenic transcription factor Sry-type HMG box (SOX) 9 in inner meniscus cells [8] . Inhibition of the Rho family GTPase ROCK, the major regulator of the actin cytoskeleton, also stimulates SOX9-dependent COL2A1 transactivation in inner meniscus cells [9] .
Several transcription factors and coactivators, such as transforming growth factor-β receptor-regulated Smad3, Scleraxis, E47, and p300, cooperatively modulate SOX9-dependent transcription by interacting with SOX9 in chondrocytic cells [10] . However, the crosstalk between SOX9 and other transcription modulators on COL2A1 upregulation remains unclear in meniscus cells.
Meniscal injury located in the avascular inner zone has poor healing potential even after meniscal repair compared with that in the outer zone [11, 12] . Trials using the major angiogenic factor, vascular endothelial growth factor (VEGF), have failed to promote the healing of meniscal injuries in the avascular inner zone [13] [14] [15] . These angiogenic factor-based treatments for enhancing meniscal healing may be inhibited by the deposition of endogenous anti-angiogenic factors such as chondromodulin-I and endostatin in the inner region of the meniscus [7, 16] . Based on these findings, we considered that the activation of chondrocytic gene expression may have a key role in promoting the healing of inner meniscus injury. In this study, we analyzed the epigenetic regulation of COL2A1 4 transactivation in chondrocytic inner meniscus cells. Furthermore, we investigated the role of SOX9-related transcriptional complex on COL2A1 expression under the inhibition of ROCK.
Materials and methods

Cells and cell culture
Institutional Review Board approval and informed consent were obtained before all experimental studies. Macroscopically intact lateral menisci were obtained at total knee arthroplasty in patients suffering from medial compartmental osteoarthritis of the knee (n = 6). Inner and outer meniscus cells were prepared from the undegenerated meniscal samples as described [6] [7] [8] [9] . In brief, synovial and capsular tissues were removed from the meniscus. Middle segments of the menisci were assessed for histological analyses (Supplemental Fig. 1 were performed using anti-SOX9 antibody (1:1000) and rabbit anti-Smad2/3 antibody (1:1000, Millipore, Temecula, CA). A bovine serum albumin solution without the primary antibody was used as a negative control. Relative amounts of detected proteins were compared with ROCKi-free controls using Image J 1.31 [7] . Nuclear fractions of inner meniscus cells were prepared in the presence or absence of ROCKi (1 μM, 2 h) as described [8, 9, 17] . Twenty percent volume of nuclear fraction was loaded as an input fraction. Forty percent volume of extract was incubated with rabbit anti-Smad3-specific antibody (Abcam, Cambridge, UK) and protein G beads (Sigma) for 4 h at 4°C.
The following western blot analysis was performed using an anti-SOX9 antibody.
Quantitative real-time PCR
RNA samples were obtained from cultured meniscus cells. Total RNAs were isolated using ISOGEN reagent (Nippon Gene, Toyama, Japan). RNA samples (500 ng) were reverse-transcribed with ReverTra Ace (Toyobo, Osaka, Japan). The following specific primer sets were used: SOX9, COL2A1, and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) [18, 19] . Quantitative real-time PCR analyses were performed using FastStart DNA Master SYBR Green I kit (Roche Diagnostics, Mannheim, Germany). The cycle number crossing the signal threshold was selected in the linear part of the amplification curve. Amplification data of G3PDH were used for normalization. Relative mRNA levels were normalized with the level of ROCKi-free condition for every sample. 6 
Chromatin immunoprecipitation (Chromatin IP)
Chromatin IP assays were performed as described [8, 9] . Inner meniscus cells were maintained in ROCKi (1 μM)-supplemented conditions for 2 h after serum-free starvation. After crosslinking step, nuclear fraction was collected. The sonicated cell lysates were suspended in nuclear lysis buffer. The 10% volume of supernatant was stocked as an input sample. The half of each remaining sample was incubated for 12 h with mouse anti-SOX9 antibody (Sigma) or rabbit anti-Smad3-specific antibody (Abcam). The remaining supernatant was incubated with mouse (or rabbit) IgG and protein G beads as a control. Input fraction DNAs, DNA fragments immunoprecipitated with endogenous SOX9 (or Smad3), and DNAs in IgG controls were purified. PCR reactions were performed using the primer set to amplify specific regions of human COL2A1 promoter and enhancer [8] , and allowed to proceed for 30 cycles.
Statistical analysis
All experiments were repeated three times independently. The expression of several genes and proteins in response to ROCKi treatments were similar among the meniscus cells from all the donors.
Data were expressed as means with standard deviations. Mean values were compared with Mann-Whitney U test. Significance was set at p < 0.05.
Results
Collagen synthesis in ROCKi-treated human meniscus cells
Type I collagen (COL1) deposition was observed around the nucleus of inner meniscus cells (Fig. 1A,   red) . Type II collagen (COL2) distributed in the cytoplasm of inner cells (Fig. 1A, green) . In outer meniscus cells, intracellular COL1 was more detected than in inner cells (Fig. 1A) . However, COL2 signal was weak in outer cells (Fig. 1A, yellow) . COL1-COL2 double positive cell ratio was increased by 1 μM of ROCKi treatment (12 h) in inner cells (Fig. 1B) . ROCKi did not affect the ratio of 7 COL2-positive outer cells (Fig. 1C) .
Chondrocytic gene expression in meniscus cells
ROCKi treatment increased expression of chondrogenic transcription factor SOX9 in inner meniscus cells ( Fig. 2A) . SOX9 gene expression was increased to 2.1-, 12.5-, and 2.7-fold levels of untreated cells by ROCKi (0.1, 1, and 10 μM, respectively) in inner meniscus cells. In outer meniscus cells, SOX9 expression was enhanced to 3.9-and 2.5-fold levels of control in the presence of 1 and 10 μM ROCKi, respectively ( Fig. 2A) . Expression of chondrocytic ECM molecule COL2A1 was increased to 13.8-fold level of control by 1 μM of ROCKi in inner cells (Fig. 2B ). In addition, ROCKi treatment (1 and 10 μM) increased COL2A1 expression in outer cells (Fig. 2B) . The highest expression of SOX9 and COL2A1 was induced by 1 μM of ROCKi treatment in inner meniscus cells.
Nuclear translocalization of SOX9 and Smad2/3 in ROCKi-treated inner meniscus cells
ROCK inhibition affected cellular morphology of inner meniscus cells (Fig. 3A, red) . In addition, ROCKi treatment (2 h) induced nuclear translocalization of SOX9 and phosphorylated Smad2/3 (Fig.   3A, green) . SOX9 accumulated in the nuclear fraction was slightly increased by ROCKi (Fig. 3B ).
Nuclear translocalization of Smad3 was also enhanced by 1 μM of ROCKi (Fig. 3C) . IP analyses revealed that the association between SOX9 and Smad3 was increased by ROCKi treatment in inner meniscus cells (Fig. 3D) .
ROCKi-mediated transcriptional regulation on the COL2A1 enhancer region
ROCKi treatment (2 h) did not show a remarkable increase of the association between SOX9 and the conserved SOX9-binding site on the COL2A1 enhancer in inner meniscus cells (Fig. 4, A and B) . On the other hand, chromatin IP analysis revealed that the COL2A1 enhancer region immunoprecipitated with Smad3 increased by ROCKi treatments (Fig. 4C ).
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Discussion
The present study demonstrated that ROCK inhibition stimulated SOX9/Smad3-dependent COL2A1 expression through the immediate nuclear translocation of Smad3 in inner meniscus cells.
ROCKi treatment also increased the gene expression levels of SOX9 and COL2A1 in outer meniscus cells (Fig. 2) . However, type II collagen deposition was not affected by ROCKi in outer meniscus cells (Fig. 1, A and C) . This may be caused by extremely low expression levels of SOX9 and COL2A1 in outer meniscus cells. A few fibrochondrocytes that had a similar phenotype to inner meniscus cells might be contaminated in cultured cells derived from the outer meniscus. We consider that the early effect of ROCKi on COL2A1 expression would be influenced by the rapid activation of endogenous SOX9-Smad3 transcriptional complex, not by a newly-produced SOX9. In fibrochondrocytic inner meniscus cells, a small amount of SOX9 may be constantly activated even in the absence of ROCKi to maintain type II collagen synthesis (Fig. 3, A and B) . ROCK inhibition slightly increased the nuclear translocalization of SOX9. On the other hand, Smad3 activation was strongly induced by ROCKi (Fig.   3, A and C) . In addition, ROCKi treatment increased the complex formation between SOX9 and Smad3 (Fig. 3D) . In our previous studies, activated Smad3 can promote the SOX9-dependent transcriptional activity by strengthen the association between SOX9 and co-factor p300 [10, 20, 21] .
Based on these findings, ROCKi-mediated Smad3 phosphorylation may up-regulate the function of SOX9/Smad3-related transcriptional complex in inner meniscus cells. ROCKi treatment also increases the gene expression of SOX9 itself in human articular chondrocytes [17, 22] , mouse chondrocytic cells [23] , and human inner meniscus cells [9] . Secondary accumulation of SOX9 in the nucleus may have an important role in a sequential induction of COL2A1 expression.
Rho family small GTPases that include the Rho, Rac, and Cdc42 subfamilies regulate a variety of cellular functions such as cytoskeletal rearrangement, migration, and cell contractility [24] . RhoA/ROCK signaling, which organizes the actin cytoskeleton, modulates SOX9 expression in several chondrocytic cell types [9, 17, 23] . In this study, we could not detect a dose-dependent effect of ROCKi on type II collagen synthesis (Fig. 1) . One μM of ROCKi showed the optimal increase of SOX9/COL2A1 gene expression and type II collagen production in inner meniscus cells (Figs. 1 and   2 ). Several studies demonstrate that potential antagonism between the Rho/ROCK and Rac pathways [25, 26] . ROCK inhibits the Rho-mDia-Rac pathway, whereas Rac can antagonize ROCK action. In neuronal cells, the high level of Rho-GTP induces ROCK activation, whereas the low level of Rho-GTP preferentially activates mDia and induces Rac activation [27] . In colon carcinoma cells, ERK-MAPK signaling coordinately modulates the balance between the activation of Rho and Rac [26] .
Ras can also activate Rho, but this signaling appears to be complex. In some cells, the signaling from Ras to Rho has been reported to be positive, in others negative [24] . These findings indicate that the degree of ROCK inhibition can modulate the activation balance between Rho and Rac in a cell-type-dependent manner. We consider that a higher concentration of ROCKi can induce severe morphological changes of the meniscus cells and may negatively regulate the gene expression of SOX9 and COL2A1. Further investigations will be required to understand the complex crosstalk among Rho small GTPases for activating chondrocytic ECM syntheses in inner meniscus cells.
Several studies show that the Rho/ROCK pathway modulates the phosphorylation status of Smad2/3 [28] [29] [30] . In human breast cancer cells, Rho/ROCK can influence Smad signaling by modulating phosphorylation of the Smad linker region [28] . ROCKi treatment (10 μM) suppresses TGF-β1-induced Smad3 phosphorylation in mouse cardiomyocytes [30] . However, ROCKi does not affect Smad2/3 phosphorylation in neural crest stem cells [29] . On the other hand, several authors have demonstrated that Smads are also involved in the function of Rho/ROCK pathway. Dominant negative Smad3 inhibits the Rho activity in human keratinocyte cells [31] . Inhibitory Smad7 that antagonizes the phosphorylation of Smad2/3 can modulate the balance of Rho GTPases by inducing the TGF-β-dependent activation of Cdc42 in human prostate cancer cells [32] . TGF-β can directly regulate Rho/ROCK activity by inducing ubiquitin-mediated RhoA degradation in epithelial cells [33] .
In our study, ROCKi treatment induced the accumulation of phosphorylated Smad3 in the nucleus of inner meniscus cells (Fig. 3) . These findings suggest that the crosstalk between Rho/ROCK and Smad3 may be cell type-specific. In addition to the ROCK pathway, RhoA has another key downstream target protein kinase PKN [34] . Because the affinity of ROCKi for PKN is at least [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] times lower than that for ROCK [35] , ROCKi treatment using Y27632 may not perfectly block the RhoA signaling. We consider that the balance between Rho/ROCK activation and Smad3 phosphorylation may be influenced by the concentration and/or treatment time of ROCKi in a cell type-specific manner. In addition, the TGF-β-mediated p38 MAPK pathway may have an additional role in modulating the transcriptional complex formation between SOX9 and Smad3. Future work will be directed toward understanding the precise mechanism of ROCKi-dependent Smad3 activation in meniscus cells.
In conclusion, ROCK inhibition can stimulates SOX9/Smad3-dependent COL2A1 expression through the cooperative activation of Smad3 in inner meniscus cells. ROCKi treatment may be useful to promote the fibrochondrocytic healing of the injured meniscus.
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